American Society of Hematology Annual Meeting

MDM2 Inhibitor Shows Promise For Patients With AML

December 24th 2019, 12:00am


New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

Real-World Data Shows Promise for Patients on CAR-T Therapy

December 20th 2019, 12:00am


Real-world data shows that CAR-T therapy can lower costs for patients with pre-existing comorbidities outside of the clinical setting.

Three-Drug Combination Improves Progression-Free Survival in Patients with Multiple Myeloma

December 11th 2019, 3:00am


Expanding a combination from two drugs to three may lengthen the time until disease progression for patients with relapsed or refractory multiple myeloma.

Investigational Oral Chemotherapy Boosts Survival in Older Patients with AML

December 11th 2019, 1:00am


Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

Genomic Sequencing Could Individualize Diagnosis, Treatment of Myeloid Cancers

December 10th 2019, 11:00pm


Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.

Immunotherapy Is Superior to Chemotherapy for Children and Young Adults with Relapsed B-Acute Lymphoblastic Leukemia

December 10th 2019, 7:00pm


In a phase 3 clinical trial, Blincyto (blinatumomab), a type of immunotherapy, improved survival and showed fewer side effects in young patients.

Ibrutinib and Rituximab Improve Progression-Free Survival for Patients with CLL

December 10th 2019, 1:00am


Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

Clinical Trial Data Highlights Stark Socioeconomic Disparities in Survival Rates Among Children with AML

December 8th 2019, 11:00pm


New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.

African American Patients Unnecessarily Excluded From AML Clinical Trials

December 8th 2019, 9:00pm


Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.

Mosunetuzumab Produces Complete Remissions in Patients with Non-Hodgkin Lymphoma

December 8th 2019, 6:00pm


Some patients with non-Hodgkin lymphoma may soon have a treatment option that could offer complete remission, according to new data presented at the American Society of Hematology 2019 Annual Meeting.